Migraine prevalence in male to female transsexuals on hormone therapy.
Neurology Program, University of Toronto, Ontario, Canada. tamara.pringsheim@utoronto.ca
Tamara
T
Pringsheim
Louis
L
Gooren
D000293:Adolescent; D000328:Adult; D000368:Aged; D000726:Androgen Antagonists / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology; D004967:Estrogens / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000139:chemically induced / Q000453:epidemiology* / Q000209:etiology; D020325:Migraine with Aura / Q000139:chemically induced / Q000453:epidemiology / Q000209:etiology; D009426:Netherlands / Q000453:epidemiology; D009569:Nitric Oxide / Q000378:metabolism; D015995:Prevalence; D012686:Septal Nuclei / Q000033:anatomy & histology; D012737:Sex Factors; D011795:Surveys and Questionnaires; D014189:Transsexualism; D014664:Vasodilation / Q000187:drug effects
D000726:Androgen Antagonists; D004967:Estrogens; D009569:Nitric Oxide